News

TOKYO, October 28, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) announced today that the United States (“U.S.”) Food and Drug Administration (FDA) has granted Fast Track designation based on nonclinical and clinical data for the development of ASP5354, an imaging agent being investigated for intraoperative ureter visualization in patients...

TOKYO, October 20, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP0367/MA-0211 (“ASP0367”) as a potential treatment for primary mitochondrial myopathies (PMM). PMM is a complex mitochondrial disease in which genetic mutations...

42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented TOKYO, OCTOBER 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, “Astellas”) today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2020...

- Accelerate Rx + ® business by acquiring innovative technology for ultra-small implantable medical devices and world-class talent in the bioelectronics field - TOKYO and Berkeley, CA., October 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Iota Biosciences, Inc. (Co-founders and Co-CEOs: Michel Maharbiz, Ph.D. and Jose Carmena, Ph.D., “iota”)...

- Durable Responses Observed in Patients Who Had Previously Received Immunotherapy but Were Ineligible for Cisplatin in Locally Advanced or Metastatic Setting - TOKYO and BOTHELL, Wash. -- October 12, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the second cohort of...